![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca and Merck’s Lynparza Gets EU Nod for High-Risk Early Breast Cancer
AstraZeneca and Merck’s Lynparza Gets EU Nod for High-Risk Early Breast Cancer
AstraZeneca and Merck’s Lynparza (olaparib) has received approval from the European Commission as a monotherapy or in combination with endocrine therapy as an adjuvant treatment for adults with human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer.
The approval is specifically for patients with germline BRCA1/2 mutations previously treated with neoadjuvant or adjuvant chemotherapy.
The approval was supported by results of a phase 3 clinical trial in which Lynparza demonstrated statistically significant improvements in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers or death by 42 percent compared with placebo.
Lynparza is a PARP inhibitor that prevents an enzyme from repairing cancer cells. On March 11, the FDA approved the drug for the same indication.
Upcoming Events
-
18Jul
-
21Oct